CN116855455B - iPS诱导定向分化成神经干细胞（iNSC）的方法及应用 - Google Patents
iPS诱导定向分化成神经干细胞（iNSC）的方法及应用 Download PDFInfo
- Publication number
- CN116855455B CN116855455B CN202311119527.1A CN202311119527A CN116855455B CN 116855455 B CN116855455 B CN 116855455B CN 202311119527 A CN202311119527 A CN 202311119527A CN 116855455 B CN116855455 B CN 116855455B
- Authority
- CN
- China
- Prior art keywords
- cells
- monoclonal antibody
- caveolin1
- ips
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004069 differentiation Effects 0.000 title claims abstract description 23
- 210000001178 neural stem cell Anatomy 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 16
- 230000001939 inductive effect Effects 0.000 title claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 230000008672 reprogramming Effects 0.000 claims abstract description 25
- 210000000130 stem cell Anatomy 0.000 claims abstract description 25
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 13
- 239000002609 medium Substances 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 239000006143 cell culture medium Substances 0.000 claims description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 abstract description 17
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 150000001413 amino acids Chemical group 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 19
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 15
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- -1 nanog Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000003727 Caveolin 1 Human genes 0.000 description 4
- 108090000026 Caveolin 1 Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 102000008730 Nestin Human genes 0.000 description 4
- 108010088225 Nestin Proteins 0.000 description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 210000005055 nestin Anatomy 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010008748 Chorea Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 208000012601 choreatic disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 101150111214 lin-28 gene Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 101100510259 Caenorhabditis elegans klf-2 gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 2
- 101100310645 Mus musculus Sox15 gene Proteins 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 108010050254 Presenilins Proteins 0.000 description 2
- 102000015499 Presenilins Human genes 0.000 description 2
- 101150037203 Sox2 gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 101100257370 Xenopus laevis sox3-a gene Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 108091054189 miR-196a stem-loop Proteins 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108010055896 polyornithine Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 101150089855 sox3 gene Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000715467 Homo sapiens Caveolin-1 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 108050004784 Huntingtin Proteins 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000038561 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150026563 NR4A2 gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 101150089079 PS1 gene Proteins 0.000 description 1
- 101150023107 PS2 gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 101150099498 SOX1 gene Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000055581 human CAV1 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150105127 klf1 gene Proteins 0.000 description 1
- 108091008792 l-Myc Proteins 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 108091008800 n-Myc Proteins 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及iPS诱导定向分化成神经干细胞（iNSC）的方法及应用。本发明提供了一种将红细祖细胞通过重编程制备成为ips细胞后，经过诱导获得了诱导性神经干细胞的方法。在ips诱导为神经干细胞的过程是通过在添加有窖蛋白1抑制剂的诱导分化培养基中实现的。所述的窖蛋白1抑制剂是特异性针对窖蛋白1的单克隆抗体Caveolin1‑4B7。通过添加相应的抗体，能够使得诱导效率大幅提高。
Description
技术领域
本申请涉及生物领域，具体的涉及干细胞制备方法，具体的涉及iPS诱导定向分化成神经干细胞（iNSC）的方法及应用。
背景技术
随着干细胞技术的不断发展，多能干细胞在组织工程、再生医学等领域的应用越来越广泛。体细胞诱导成为多潜能性干细胞(iPS)的研究成果被誉为生命科学领域新的里程碑。由于iPS细胞既避免免疫排斥,又不涉及伦理道德问题,因此具有广泛且重要的临床应用价值。尤其是神经干细胞的研究，对于神经退行性疾病的治疗有着重要的意义。
iPSC是利用反转录病毒、腺病毒等载体，将某些特殊的转录因子导入终末分化的成体细胞，重编程诱导成具有潜在分化功能的干细胞。将成鼠的成纤维细胞重编程成iPSC，它具有与小鼠胚胎干细胞(ESC)十分相似的生理特性。2007年，iPSC技术在人类体细胞中得以应用。2009年，Ebea等建立了人脊髓性肌萎缩症(SMA)iPSC模型并应用于SMA的发病机制和治疗学研究。AD是老年人常见的神经系统变性病，临床特征为隐袭起病，进行性智能衰退，多伴有人格改变。病因迄今未明。病理上，患者呈弥漫性脑萎缩，并出现老年斑、神经纤维缠结、海马椎体细胞颗粒空泡变性及神经元缺失。研究发现，导致AD的主要遗传因素为载脂蛋白E、早老素(presenilin，PS)1、PS2、淀粉样肽前体蛋白基因突变。Yagi等建立了PS1和PS2基因突变的iPSC系，并诱导分化为神经元细胞。该神经元细胞内较正常对照组有较多的淀粉样蛋白42分泌，证实了淡粉样蛋白聚集导致AD发病的机制。HD是一种呈常染色体显性遗传的大脑变性疾病，主要症状为舞蹈样动作和进行性认知障碍。病因主要是由于IT15基因中出现多个串联的CAG重复序列，由此产生异常的神经性舞蹈病蛋白，从而造成细胞毒性而发生神经细胞的变性改变。当CAG重复超过4O个时即可导致本病的发生，CAG重复序列扩增越多，患者的起病年龄越早。研究发现，HD患者iPSC来源的纹状体神经元和神经前体细胞具有和HD患者相似的CAG重复序列，易于受到损伤后凋亡。研究也发现，miR-196a可降低HD患者来源的iPSC诱导的神经元细胞内神经性舞蹈病蛋白的病理性聚集及过度表达，从而证明miR-196a对HD的潜在治疗价值。
此前的研究显示，窖蛋白1（Caveolin1）参与调节间充质干细胞的分化，研究也证实了人脂肪间充质干细胞分化为类多巴胺能神经元细胞中在人脂肪间充质干细胞向类多巴胺能神经元的分化过程中窖蛋白1表达减少，下调窖蛋白1表达能够促进人脂肪间充质干细胞向类多巴胺能神经元分化，而且可提高细胞中酪氨酸羟化酶、Lmx1a及Nurr1的表达，窖蛋白1在干细胞向多巴胺能神经元分化中起负向调控作用。但是目前，针对IPS细胞诱导成为神经干细胞是否也可以通过下调窖蛋白1（Caveolin1）来实现还没有相关研究。神经干细胞是一类具有分裂潜能和自更新能力的母细胞，它可以通过不对等的分裂方式产生神经组织的各类细胞。神经干细胞具有分化为神经神经元、星形胶质细胞和少突胶质细胞的能力，能自我更新，从而为神经组织提供大量的功能性细胞，在多种神经系统疾病方面具有着重要的应用价值和研究意义。
发明内容
本发明针对现有技术的不足，提供了一种将红细祖细胞通过重编程制备成为ips细胞后，经过诱导获得了诱导性神经干细胞的方法。
具体的，所述红细胞祖细胞可以是商业购买的，也可以是直接从血液中分离制备获得的。
所述分离，是采用RosetteSep™ Human Progenitor Cell Basic Pre-Enrichm祖细胞预富集混合物后分离制备的。
进一步的，所述红细胞祖细胞通过电转化 Epi5TM Episomal iPSC 重编程试剂盒中的重编程因子后在干细胞培养基中培养获得相应的ips细胞。
进一步的，重编程因子是本领域熟知的“有助于将靶细胞重编程为诱导性多能干细胞的因子”，具体的是能够帮助诱导靶细胞重编程为诱导性多能干细胞的因子，其中所述因子选自Oct3/4和属于Myc、Klf和Sox因子家族的因子，这类重编程因子包括例如，Oct3/4、Sox2、Sox1、Sox3、c-Myc、n-Myc、l-Myc、Klf1、Klf2、Klf4和Klf5等因子，或这些因子的具有保留的重编程能力的突变体。所述对重编程的帮助可为如下形式：例如将细胞的甲基化模式变为与干细胞类似的甲基化模式，将细胞的表达模式转换为干细胞的表达模式，或者通过将组蛋白的结合调节为与干细胞中所观察到的相类似来影响聚合核DNA的构象，其中，通过适合的重编程因子，上述的每种形式都可单独或以组合的方式得以实现。除上述的因子之外，技术人员还了解鉴定其他适合的重编程因子的方法，诸如亚硫酸氢盐基因组测序、RT-PCR、实时PCR、微列阵分析、染色体组型分析、畸胎瘤形成、碱性磷酸酶染色等方法。
在一些方面，重编程载体中将包括编码Sox和Oct(特别是Oct3/4)的核酸。例如，一个或多个重编程载体可以包含编码Sox2、Oct4、Nanog和任选Lin28的表达盒，或编码Sox2、Oct4、Klf4和任选c-Myc的表达盒，或编码Sox2、Oct4和任选Esrrb的表达盒，或编码Sox2、Oct4、Nanog、Lin-28、Klf4、c-Myc和任选SV40大的T抗原的表达盒。编码这些重编程因子的核酸可以包含在同一表达盒中、不同表达盒中、同一重编程载体中，或不同重编程载体中。Oct4和Sox基因家族的一些成员(Sox1、Sox2、Sox3和Sox15)已经被鉴定为参与诱导过程的关键性转录调节子，其缺失会使诱导不能进行。另一方面，另外的基因，包括Klf家族的一些成员(Klf1、Klf2、Klf4和Klf5)、Myc家族的一些成员(c-Myc、L-Myc和N-Myc)、Nanog和Lin28已经被鉴定为增强诱导效率。Oct4(Pou5f1)是八聚合体(octamer，″Oct″)家族转录因子之一，在维持多能+性方面具有关键作用。Oct4 细胞例如卵裂球和胚胎干细胞中Oct4的缺失会导致自发的滋养层分化，因此Oct4的存在产生胚胎干细胞的多能性和分化潜力。″Oct″家族中的多个其它基因，包括Oct4的近亲Oct1和Oct6，不能引发诱导，因此证明了Oct-4在诱导过程中的专有性。与Oct4类似，Sox基因家族与维持多能性相关，虽然其与多潜能(multipotent)和单能干细胞相关，而Oct4与此相反，Oct4专有性地在多能干细胞中表达。虽然Sox2是用于重编程诱导的最初基因，但是发现Sox家族中的其它基因也在诱导过程中同样起作用。Sox1以类似于Sox2的效率产生iPS细胞，基因Sox3、Sox15和Sox18也产生iPS细胞。
具体的，所述ips分化为神经干细胞是通过在添加有窖蛋白1抑制剂的诱导分化培养基中实现的。
具体的，所述的窖蛋白1抑制剂是特异性针对窖蛋白1的单克隆抗体Caveolin1-4B7。
该单克隆抗体Caveolin1-4B7通过测序，鉴定获得其重链可变区序列如SEQ IDNO：1所示，轻链可变区序列如SEQ ID NO:2所示。
具体的，通过亲和力测定，本发明的单克隆抗体Caveolin1-4B7与表位肽的亲和力为1.53nM，亲和特性较好。
在一些实施方案中，本发明的重链可变区包含与选自 SEQ ID NO :1的氨基酸序列具有至少90%、91%、92%、93%、94%、95%、96%、97%、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成；或者
( i ）包含选自 SEQIDNO :1的氨基酸序列或由所述氨基酸序列组成：或者
( ii ）包含与选自 SEQ ID NO :1的氨基酸序列相比具有1个或多个（优选不超过10个，更优选不超过5、4、3、2、1个）的氨基酸改变（优选氨基酸置换，更优选氨基酸保守置换）的氨基酸序列或由所述氨基酸序列组成。
在一些实施方案中，本发明的轻链可变区
i ）包含与选自 SEQ ID NO :2的氨基酸序列具有至少90%、91%、92%、93%、94%、95%、96%、97%、98％或99％同一性的氨基酸序列或由所述氨基酸序列组成；或者
ii )包含选自 SEQ ID NO :2的氨基酸序列或由所述氨基酸序列组成；或者
( ii ）包含与选自 SEQ ID NO :2的氨基酸序列相比具有1个或多个（优选不超过10个，更优选不超过5、4、3、2、1个）的氨基酸改变（优选氨基酸置换，更优选氨基酸保守置换）的氨基酸序列或由所述氨基酸序列组成。
保守性氨基酸置换是优选的，即，例如，作为极性酸性氨基酸的天冬氨酸/谷氨酸；作为极性碱性氨基酸的赖氨酸/精氨酸/组氨酸；作为非极性或疏水性氨基酸的亮氨酸/异亮氨酸/甲硫氨酸/缬氨酸/丙氨酸/甘氨酸/脯氨酸；作为极性或不带电的亲水性氨基酸的丝氨酸/苏氨酸。保守性氨基酸置换还包括基于侧链的分组。例如，具有脂肪族侧链的一组氨基酸是甘氨酸、丙氨酸、缬氨酸、亮氨酸和异亮氨酸；具有脂肪族-羟基侧链的一组氨基酸是丝氨酸和苏氨酸；具有含酰胺侧链的一组氨基酸是天冬酰胺和谷氨酰胺；具有芳香族侧链的一组氨基酸是苯丙氨酸、酪氨酸和色氨酸；具有碱性侧链的一组氨基酸是赖氨酸、精氨酸和组氨酸；具有含硫侧链的一组氨基酸是半胱氨酸和甲硫氨酸。例如，可以合理预期：将亮氨酸替换为异亮氨酸或缬氨酸、将天冬氨酸替换为谷氨酸、将苏氨酸替换为丝氨酸、或类似地将氨基酸替换为结构上相关的氨基酸将不会对得到的多肽的性质产生大的影响。可以通过测定多肽的比活性容易地确定氨基酸替换是否产生功能性抗体。
为了iPS细胞的临床施用，方法还可以包括使iPS细胞分化为分化的细胞，例如，心肌细胞、造血细胞、肌细胞、神经元、成纤维细胞、胰腺细胞、肝细胞或上皮细胞。在另一个方面，可以公开从如上文所述的iPS细胞群体分化而来的分化的细胞、组织或器官。组织可以包括神经、骨、肠、上皮、肌肉、软骨或心脏组织；器官可以包括脑、脊髓、心脏、肝、肾、胃、肠或胰腺。
本发明的培养基通常还包括至少必需氨基酸(即His、Ile、Leu、Lys、Met、Phe、Thr、Try、Val)以及某些非必需氨基酸。如果细胞系不能合成氨基酸或细胞系不能产生足够量的氨基酸以支持最大生长，则非必需氨基酸通常包括在细胞培养基中。此外，哺乳动物细胞也可以使用谷氨酰胺作为主要能量来源。包含的谷氨酰胺的浓度通常高于其他氨基酸(2-8mM)。 本发明的培养基还可包含血清。血清是凝固血液的上清液。血清组分包括附着因子、微量营养物质(例如微量元素)、生长因子(例如激素、蛋白酶)和保护性元素(例如抗毒素、抗氧化剂、抗蛋白酶)。血清可从多种动物来源获得，包括人、牛或马血清。当包含在根据本发明的细胞培养基中时，通常以5-10％(体积)的浓度添加血清。优选的细胞培养基是无血清的。细胞培养基可任选地包含一种或多种缓冲剂。合适的缓冲剂包括但不限于N-[2-羟乙基]-哌嗪-N'-[2-乙磺酸](HEPES)、MOPS、MES、磷酸盐、碳酸氢盐和适用于细胞培养应用的其它缓冲剂。合适的缓冲剂是提供缓冲能力而对培养的细胞没有实质细胞毒性的缓冲剂。合适的缓冲剂的选择在细胞培养领域的普通技术范围内。
优选的，本发明的培养基是DMEM/F12中添加2% B27 Supplement、1% N2Supplement，20 ng/ml bFGF，10-500μg/mL Caveolin1-4B7单抗组成。
有益效果：本发明提供了一种将红细祖细胞通过重编程制备成为ips细胞后，经过诱导获得了诱导性神经干细胞的方法。在ips诱导为神经干细胞的过程是通过在添加有窖蛋白1抑制剂的诱导分化培养基中实现的。所述的窖蛋白1抑制剂是特异性针对窖蛋白1的单克隆抗体Caveolin1-4B7。通过添加相应的抗体，能够使得诱导效率大幅提高。
附图说明
图1 单克隆抗体纯化后SDS-PAGE图
图2 单克隆抗体Caveolin1-4B7 Western blot特异性鉴定结果图
图3 单抗Caveolin1-4B7对窖蛋白1表达的影响结果
图4 单抗对ips细胞向神经干细胞的分化影响
实施方式
下面将参照附图更详细地描述本发明的具体实施例。虽然附图中显示了本发明的具体实施例，然而应当理解，可以以各种形式实现本发明而不应被这里阐述的实施例所限制。相反，提供这些实施例是为了能够更透彻地理解本发明，并且能够将本发明的范围完整的传达给本领域的技术人员。
尽管本文使用了特定的术语，但它们仅用于一般性和描述性的意义，而不是为了限制的目的。除非另有定义，否则本文使用的所有技术和科学术语具有与本公开描述的主题所属领域的普通技术人员通常理解的相同的含义。
实施例1 窖蛋白1（Caveolin1）抑制性单克隆抗体的制备
根据NM_012232.6人Caveolin1的氨基酸序列，通过Kolaskar-Tongaonkar抗原决定簇分析软件，选择高免疫原性位点同时结合Caveolin1关键活性区域，选取了会影响蛋白活性关键区域以及具有高免疫原性的表位活性肽：TVSKLLEKVRKVSVNVKTVRGSL，委托南京金斯瑞生物科技进行合成，检测多肽纯度达到99.5%，将其与血蓝蛋白（KLH） 偶联； 备用。
将偶联后的表位活性肽溶解后与弗氏完全佐剂以1∶1的体积比充分乳化。取3只6周龄BALB/c雌鼠采用皮下多点注射的方法进行免疫，共免疫4次，每两周进行一次免疫，剂量为每只60µg。对血清免疫效价最高的1号小鼠，在细胞融合前3d，对脾脏进行加强免疫，剂量为50µg。
将生长状态良好的SP2/0骨髓瘤细胞与1号免疫小鼠的脾脏细胞分别用无血清1640培养基洗涤至无明显颗粒后，以1：9的数量比进行混合，离心弃上清。轻摇离心管使细胞均匀分散后，缓慢加入1mL37℃预热的PEG1500并轻轻吹打混匀，60s后，立即加入预热的20mL1640培养基终止融合，然后加入20%FBS-HAT-1640培养基悬浮细胞并混匀。将混匀后的培养基均匀铺于96孔板中，置于5%CO2、37℃的培养箱中培养，每天跟踪观察，融合后8d用10%FBS-HT-1640培养液换液，当克隆长至孔底面积的1/3～1/2时，通过ELISA以表位活性肽作为正筛，以KLH作为反筛，筛选阳性的克隆共计89个。将阳性克隆中较强反应特性的20个克隆通过有限稀释法对细胞集落数目少且阳性值高的孔进行克隆化，经过4次亚克隆后即得到1株能稳定分泌特异性单克隆抗体的细胞株命名为Caveolin1-4B7。
选用8周以上的BALB/c小鼠，在接种杂交瘤细胞10天前，将0.5mL的液体石蜡注射入小鼠腹腔。收集生长良好的杂交瘤细胞Caveolin1-4B7，调整为每毫升1×106个，每只小鼠腹腔注射细胞悬液0.5mL。10d后，小鼠腹部明显膨大后消毒腹部皮肤，用注射器抽取腹腔腹水。离心吸取淡黄色腹水，将饱和硫酸铵溶液以1∶1的体积比缓慢加入抽取的腹水中，混匀，直到出现白色沉淀。离心去上清，用PBS（pH7.45）溶液溶解沉淀，使用亲和层析柱进行抗体纯化，纯化后的抗体采用SDS-PAGE进行鉴定。结果如图1所示。
实施例2 单克隆抗体Caveolin1-4B7效价测定
将表位活性肽用碳酸氢盐缓冲液稀释至质量浓度为1µg/mL，用酶联免疫吸附（ELISA）板包被，4℃过夜。洗板1次后，加入封闭液，37℃放置2h。洗板5次，加入单克隆抗体Caveolin1-4B7腹水，从1∶1000开始进行倍比稀释，稀释6个梯度，空白为磷酸盐缓冲溶液（PBS），设置重复对照，37℃孵育30min。洗板5次，加入HRP-羊抗鼠二抗，37℃孵育30min。洗板5次，最后加3，3'，5，5'-四甲基联苯胺（TMB）底物显色剂，37℃反应10min。加终止液，于450nm/630nm双波长处检测光密度（OD）值。经测定，小鼠腹水的效价为6.4×106。
实施例3 单克隆抗体Caveolin1-4B7特异性鉴定
采用 Western blot 将大肠杆菌DH5α裂解物，血蓝蛋白，人脐带间充质干细胞裂解物，先以SDS-PAGE分离，再将凝胶蛋白带转移至硝酸纤维素膜上，与单克隆抗体Caveolin1-4B7反应后，加HRP-羊抗鼠IgG，以DAB显色。结果如图2所示。
从图2可以看出，泳道1的大肠杆菌DH5α裂解物，泳道2的雪蓝蛋白均没有特异性的条带，而泳道3的人脐带间充质干细胞裂解物中的窖蛋白1能够与本发明的单克隆抗体Caveolin1-4B7形成特异性的条带，表现出了较好的特异性。
实施例4 红细祖细胞的分离及单抗Caveolin1-4B7活性实验
采集外周血20ml，加入100μl RosetteSep™ Human Progenitor Cell BasicPre-Enrichm祖细胞预富集混合物，温育10min，转移至含有30ml人淋巴细胞分离液的SepMate TM管中1200r/min离心12min。用Stem Span TM无血清培养基重悬细胞，上述细胞计数后按5×105个细胞/孔接种于6孔板中，置于37℃、5％CO2培养箱中培养7d后，取少量细胞，采用瑞氏-吉姆萨染色液对分离培养7天后获得的红系祖细胞进行染色，并于显微镜下观察发现红系祖细胞呈圆形，大小基本抑制，并且呈现紫红色，表明分离得到了红细祖细胞。
将培养的红细祖细胞接种到96孔板中，每孔中细胞的浓度调整浓度为1×105个。将单抗Caveolin1-4B7按照200、100、50、10μg/mL以及空白对照组共培养24h后，离心，取等量细胞，用RIPA裂解缓冲液提取细胞总蛋白，经Bradford法定量后进行十二烷基硫酸钠-聚丙烯酰胺凝胶电泳。将电泳分离的蛋白质电转染至聚偏氟乙烯膜上。用含5％脱脂奶粉的PBST溶液室温封闭1h。与相应第一抗体4℃孵育过夜，再与对应的辣根过氧化物酶标记的第二抗体于37℃摇床中孵育1h。经电化学发光试剂显色后，在暗室中进行X光胶片感光；室温显影，定影，用扫描仪和凝胶成像系统记录相应条带的透射光积分吸光度值，以空白对照组中窖蛋白1/β-肌动蛋白的透射光积分吸光度值设为1进行各组定量，结果如图3所示。
从图3可以看出，单抗Caveolin1-4B7能够有效的抑制细胞中的窖蛋白1的表达，并且具有剂量依赖性的抑制效果，在200μg/mL的浓度条件下，窖蛋白1相对表达量不到0.08，抑制效果较好。
实施例5 红细祖细胞重编程为ips细胞及诱导分化为神经干细胞
将实施例4制备分离培养的红细祖细胞调整细胞数为1×106个，100μl电转缓冲液中加入 2μl Epi5TM Episomal iPSC 重编程试剂盒中的重编程因子，采用常规电转染细胞按2ml/孔接种于基质胶包被的6孔板中，置于培养箱中培养。并使用ReproTeSRTM重编程培养基隔天换液，转染后第20天，观察iPSCs可见典型的克隆，采用试剂盒检测干细胞多能性基因发现OCT4、SOX2、NANOG、KLF4和LIN28均阳性表达，表明制备获得了ips细胞。将ips克隆重新接种于基质胶包被的6孔板中，置于培养箱中培养，使用mTeSRTM培养基继续培养，备用。
单抗处理组：当前述ips细胞集落密度达到70-80%汇合时，使用胰蛋白酶和EDTA分离ips细胞。用DMEM/F12培养基洗涤细胞一次后，将细胞更换到用80µg/mL Matregel和10mg/mL聚-L-鸟氨酸包被的培养皿中，细胞的密度为106个细胞/孔，培养基为DMEM/F12中添加2% B27 Supplement、1% N2 Supplement，20 ng/ml bFGF，200μg/mL Caveolin1-4B7单抗在37℃和5%CO2条件下培养。培养基隔日更换，当达到85%汇合时，细胞以1:3传代。
自然分化组：当前述ips细胞集落密度达到70-80%汇合时，使用胰蛋白酶和EDTA分离ips细胞。用DMEM/F12培养基洗涤细胞一次后，培养基为DMEM/F12中在37℃和5%CO2条件下培养。培养基隔日更换，当达到85%汇合时，细胞以1:3传代。
无单抗对照组：当前述ips细胞集落密度达到70-80%汇合时，使用胰蛋白酶和EDTA分离ips细胞。用DMEM/F12培养基洗涤细胞一次后，将细胞更换到用80µg/mL Matregel和10mg/mL聚-L-鸟氨酸包被的培养皿中，细胞的密度为106个细胞/孔，培养基为DMEM/F12中添加2% B27 Supplement、1% N2 Supplement，20 ng/ml bFGF在37℃和5%CO2条件下培养。培养基隔日更换，当达到85%汇合时，细胞以1:3传代。
诱导一周后，将二组培养的细胞进行神经干细胞标志物Nestin染色， 随机选取10个200倍视野进行观察， 分别计算Nestin阳性细胞总数占视野中细胞总数的比例， Nestin阳性细胞率（%）＝阳性细胞数/总细胞数×100%。 以上实验每次设3个平行组， 作统计分析，结果如图4所示。
从图4可以看出，自然分化组相比于无单抗对照组和单抗处理组，Nestin阳性细胞率较低，差异及其显著（P<0.01）。另外，相对于没有采用单抗处理的诱导方式，添加了单抗处理后，由于窖蛋白1在干细胞向神经细胞分化中起负向调控作用，因此，能够显著的抑制窖蛋白1的表达，进而促进ips细胞向神经干细胞的分化， Nestin阳性细胞率达到（96.31±4.83）%，显著的高于没有采用单抗的对照组。
最后应说明的是：以上各实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述各实施例对本发明进行了详细的说明，但本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (5)
1.一种红细祖细胞来源的iPS细胞诱导定向分化成神经干细胞iNSC的方法，其特征在于，将红细祖细胞重编程制备并获得ips细胞，将所述ips细胞在诱导分化培养基中培养后获得神经干细胞，所述的诱导分化培养基组成为DMEM/F12中添加2% B27 Supplement、1%N2 Supplement，20 ng/ml bFGF，10-200μg/mL Caveolin1-4B7单抗组成；其中，所述Caveolin1-4B7单抗的重链可变区序列如SEQ ID NO：1所示，轻链可变区序列如SEQ ID NO:2所示。
2.如权利要求1所述的方法，其特征在于，所述的将红细祖细胞重编程制备并获得ips细胞是通过将红细祖细胞通过电转化 Epi5TM Episomal iPSC 重编程试剂盒中的重编程因子后在干细胞培养基中培养获得ips细胞。
3.如权利要求1或2所述的方法，其特征在于，红细祖细胞是商业购买的或者直接从人血液中分离获得的。
4.一种特异性抑制窖蛋白1活性的单克隆抗体，其命名为Caveolin1-4B7，该单克隆抗体的重链可变区序列如SEQ ID NO：1所示，轻链可变区序列如SEQ ID NO:2所示。
5.一种用于诱导红细祖细胞来源的iPS细胞分化为神经干细胞的培养基，其特征在于，所述培养基组成为DMEM/F12中添加2% B27 Supplement、1% N2 Supplement，20 ng/mlbFGF，10-200μg/mL Caveolin1-4B7单抗组成；其中，所述Caveolin1-4B7单抗的重链可变区序列如SEQ ID NO：1所示，轻链可变区序列如SEQ ID NO:2所示。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311119527.1A CN116855455B (zh) | 2023-09-01 | 2023-09-01 | iPS诱导定向分化成神经干细胞（iNSC）的方法及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311119527.1A CN116855455B (zh) | 2023-09-01 | 2023-09-01 | iPS诱导定向分化成神经干细胞（iNSC）的方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116855455A CN116855455A (zh) | 2023-10-10 |
| CN116855455B true CN116855455B (zh) | 2023-11-24 |
Family
ID=88225284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311119527.1A Active CN116855455B (zh) | 2023-09-01 | 2023-09-01 | iPS诱导定向分化成神经干细胞（iNSC）的方法及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116855455B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116966202B (zh) * | 2023-09-22 | 2023-12-01 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成的神经干细胞联合药物用于治疗阿尔茨海默症的用途 |
| CN118085099B (zh) * | 2024-04-17 | 2024-06-21 | 羽铂精制生物技术(成都)有限公司 | 一种单克隆抗体以及一种高效的iPSC诱导方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115028730A (zh) * | 2022-05-17 | 2022-09-09 | 诺赛联合(北京)生物医学科技有限公司 | 一种成体干细胞衍生的类器官制备方法 |
| WO2023149407A1 (ja) * | 2022-02-01 | 2023-08-10 | 国立大学法人京都大学 | 肺間葉細胞の製造方法および肺間葉細胞 |
-
2023
- 2023-09-01 CN CN202311119527.1A patent/CN116855455B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023149407A1 (ja) * | 2022-02-01 | 2023-08-10 | 国立大学法人京都大学 | 肺間葉細胞の製造方法および肺間葉細胞 |
| CN115028730A (zh) * | 2022-05-17 | 2022-09-09 | 诺赛联合(北京)生物医学科技有限公司 | 一种成体干细胞衍生的类器官制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| Caveolin-1 Derived from Brain Microvascular EndothelialCells Inhibits Neuronal Differentiation of NeuralStem/Progenitor Cells In Vivo and In Vitro;Yue Li等;《Neuroscience》;第448卷(第10期);第172-190页 * |
| Caveolin-1 downregulation promotes the dopaminergic neuron-like differentiation of human adipose-derived mesenchymal stem cells;Chao Han等;《Neural Regeneration Research》(第4期);第1-10页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116855455A (zh) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116855455B (zh) | iPS诱导定向分化成神经干细胞（iNSC）的方法及应用 | |
| US20220290099A1 (en) | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders | |
| Kaneko et al. | Musashi1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells | |
| US7732203B2 (en) | Method for transdifferentiating mesenchymal stem cells into neuronal cells | |
| Liu et al. | Human neural progenitors derived from integration-free iPSCs for SCI therapy | |
| JP2015509719A (ja) | 神経幹細胞を調製するための培養培地およびその使用 | |
| US20120219535A1 (en) | Cranial neural crest stem cells and culture condition that supports their growth | |
| Oh et al. | Human-induced pluripotent stem cells generated from intervertebral disc cells improve neurologic functions in spinal cord injury | |
| Ogawa et al. | Immunopanning selection of A2B5-positive cells increased the differentiation efficiency of induced pluripotent stem cells into oligodendrocytes | |
| US20190322981A1 (en) | Means and methods for the generation of oligodendrocytes | |
| Sugaya et al. | How to approach Alzheimer's disease therapy using stem cell technologies | |
| US20200010800A1 (en) | Method for controlling differentiation of pluripotent stem cells | |
| Lu et al. | Retrovirus delivered neurotrophin-3 promotes survival, proliferation and neuronal differentiation of human fetal neural stem cells in vitro | |
| Lebedeva et al. | The morphofunctional properties of induced pluripotent stem cells derived from human skin fibroblasts and differentiated to dopaminergic neurons | |
| CN111732660A (zh) | 骨髓间充质干细胞和单克隆抗体联合治疗癌症 | |
| Liu et al. | Generation and characterization of induced pluripotent stem cells from mononuclear cells in schizophrenic patients | |
| Kuznetsova et al. | Human adult retinal pigment epithelial cells as potential cell source for retina recovery | |
| Schäck et al. | Induction of neuronal-like phenotype in human mesenchymal stem cells by overexpression of Neurogenin1 and treatment with neurotrophins | |
| US7041507B1 (en) | Transdiffentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells | |
| CN116966202B (zh) | iPS诱导定向分化成的神经干细胞联合药物用于治疗阿尔茨海默症的用途 | |
| US20220243174A1 (en) | Autologous cell replacement therapy for parkinson`s disease | |
| WO2015133879A1 (ko) | 체세포로부터 희소돌기아교 전구세포로의 직접교차분화 유도용 조성물 및 이의 이용 | |
| US20020132239A1 (en) | Cell lineage markers | |
| JP2019076008A (ja) | 骨細胞、軟骨細胞、脂肪細胞、または神経細胞に分化可能な前駆細胞、その作製方法、およびその使用方法 | |
| CN118085079B (zh) | 一种单克隆抗体以及一种提高诱导多能干细胞（iPSC）基因组稳定性的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |